SOD1 and acute kidney injury: Other SOD mimetic antioxidant strategies tested in preclinical AKI, such as Mito-CP, MitoTEMPO, tempol, and GC441, are not listed in clinicaltrials.gov as being in clinical development (Table 1 and Table 2) [15,45,46,62,108].